CL Biologics
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A global biologics CDMO leader from China, offering cost-effective, large-scale manufacturing from IND-enabling to commercial production for antibody and ADC therapeutics.
OncologyImmunology
Technology Platform
Hybrid biomanufacturing platform combining single-use bioreactors for clinical-scale and large-scale (up to 15,000L) stainless steel bioreactors for commercial production, integrated with digital quality systems (Biomanufacturing 4.0).
Opportunities
Capitalizing on the global demand for outsourced biologics manufacturing, especially for ADCs and large-volume commercial antibodies, by offering significant cost savings and scale unavailable from many Western CDMOs.
Risk Factors
Execution risk in bringing two massive, greenfield facilities online simultaneously and on schedule; regulatory risk in achieving and maintaining FDA/EMA compliance; and intense competition from established global and Asian CDMOs.
Competitive Landscape
Competes with global CDMO giants (Lonza, Samsung Biologics) and Chinese leaders (WuXi Biologics). Differentiates through its focus on very large-scale (15kL) stainless steel capacity in China, cost leadership, and an executive team with deep global pharma experience.